
Releases
Investors Face August 10 Deadline in ADMA Biologics Class Action
Investors who held ADMA Biologics stock between August 2024 and March 2026 have until August 10, 2026, to seek lead plaintiff status in a pending securities fraud lawsuit. The Philadelphia-based law firm Berger Montague launched the action following allegations of deceptive revenue reporting practices at the biopharmaceutical company.























